VYNE Therapeutics Inc. (VYNE) Q1 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Vine Therapeutics conference call to discuss the first quarter 2021 financial results and updates. At this time, all participants are in a listen-only mode. Following the company's formal remarks, we will open the call for your questions. Please be advised that this call is being recorded at the company's request. I will now turn the call over to Michael Wood at LifeSci Advisors. Please go ahead. Good morning, everyone, and thank you for joining us. Before we begin formal remarks, let me remind everyone you that some of the information in the press release issued this morning and on this conference call contained forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict, including statements, forecasts, and observations regarding future financial operating performance, impacts of the COVID-19 pandemic online, and observations regarding ongoing operating expenses and net revenue. These statements include observations associated with commercialization of Amnesty Consultancy in the United States. It will also include plans and expectations regarding the success, timing, and cost of clinical trials. Words that expect and reflect optimism, satisfaction with current progress, prospects or projections, as well as words such as believe, intend, expect, plan, anticipate, and similar variations identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those contained in such statements. Several factors that could cause or contribute to such differences are described in detail in Vine Therapeutics' filings with the SEC. These forward-l...